S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

Bibliographic Details
Main Authors:	Anna Sureda, Lorenzo Falchi, Sirpa Leppa, Joost Vermaat, Harald Holte, Martin Hutchings, Pieternella Lugtenburg, Sven de Vos, Pau Abrisqueta, Marcel Nijland, Reid W. Merryman, Jacob Haaber Christensen, Bjorn Wahlin, Kim Linton, Liwei Wang, Aqeel Abbas, Ali Rana, Syed Quadri, David Belada
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967800.55471.36

Similar Items

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
by: D. Belada, et al.
Published: (2022-06-01)

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: R. Cordoba, et al.
Published: (2022-06-01)

P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
by: M. R. Clausen, et al.
Published: (2022-06-01)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
by: Wojciech Jurczak, et al.
Published: (2023-08-01)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: B. E. Wahlin, et al.
Published: (2022-06-01)

P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE
by: Michael Roost Clausen, et al.
Published: (2023-08-01)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
by: Rumaisa Riaz, et al.
Published: (2023-07-01)

Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma
by: Heli Vajavaara, et al.
Published: (2022-08-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
by: Allison Rosenthal, et al.
Published: (2023-08-01)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
by: Catherine Thieblemont, et al.
Published: (2023-08-01)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
by: Andrew Ip, et al.
Published: (2023-08-01)

Management of aplastic anemia in a woman during pregnancy: a case report
by: Lugtenburg Pieternella J, et al.
Published: (2011-02-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
by: L. H. Sehn, et al.
Published: (2022-06-01)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
by: A. Vera de Jonge, et al.
Published: (2023-05-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Severe cutaneous scleromyxedema treated by lenalidomide
by: Théo Brochet, et al.
Published: (2023-09-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Expanding role of lenalidomide in hematologic malignancies
by: Ghosh N, et al.
Published: (2015-05-01)

Mechanism of action of lenalidomide in hematological malignancies
by: Kotla Venumadhav, et al.
Published: (2009-08-01)

Lenalidomide-induced diffuse alveolar hemorrhage
by: S Saheer, et al.
Published: (2014-01-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands
by: Avinash G. Dinmohamed, et al.
Published: (2018-10-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

Lenalidomide-Induced Pure Red Cell Aplasia
by: Tuphan Kanti Dolai, et al.
Published: (2014-02-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

A case of scleromyxedema responding to lenalidomide and dexamethasone
by: Sweta Rambhia, et al.
Published: (2017-01-01)

A case of severe hypothyroidism due to lenalidomide
by: Rachel A. Blair, et al.
Published: (2019-09-01)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
by: Hilma J. van der Horst, et al.
Published: (2021-02-01)

Regardless of frontiers : children's rights and global learning /
by: 384289 Harrison, Don
Published: (2008)

Cohesion as a choice : regardless of faith and identity
by: Jerard, Jolene
Published: (2021)

Simple circuits to maintain isocapnia regardless of ventilation
by: Fedorko L, et al.
Published: (2001-08-01)

Testicular Diffuse Large B-Cell Lymphoma—Clinical, Molecular, and Immunological Features
by: Marjukka Pollari, et al.
Published: (2021-08-01)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2012-01-01)

Simultaneous myelodisplasia and multiple myeloma successfully treated with lenalidomide
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

LENALIDOMIDE ASSOCIATED İMMUNE THROMBOCYTOPENIA: A CASE REPORT
by: İbrahim Halil Acar, et al.
Published: (2021-11-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2011-12-01)